By Payer Type

340B Discount Program Market Analysis

Cross-industry research covering 340B Discount Program across 1 market reportspanning Pharmaceuticals & Medical Devices — Ophthalmic Surgery.

1 Reports
1 Industries

Reports Covering 340B Discount Program

Oculoplastic Surgery Market to Reach USD 8.4 Billion by 2033 at 7.2% CAGR

Pharmaceuticals & Medical Devices — Ophthalmic Surgery·Market: USD 4.8 Billion (2025)·CAGR: 7.2%

A modest but strategically important payer category for high-cost TED biologics; 340B-eligible covered entities acquire TED biologics at or near manufacturer ceiling price, creating significant margin opportunity at qualifying academic and safety-net medical centers that conflicts with manufacturer net price realization objectives.

4%

Market Share

5.5%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments